In metastatic BC, ICIs are currently recommended as a second-line treatment in case of progression after chemotherapy, as well as a first-line treatment in PD-L1-positive patients who are not eligible for cisplatin-based combination chemotherapy. This evidence concerns the gene CD274 and breast cancer.